American deal for EFK Diagnostics

EFK Diagnostics (EFK), an AIM-listed manufacturer of healthcare equipment, has agreed to acquired the entire issued share capital of Stanbio Laboratory in a deal worth $25.5 million (£15.7 million).


EFK Diagnostics (EFK), an AIM-listed manufacturer of healthcare equipment, has agreed to acquired the entire issued share capital of Stanbio Laboratory in a deal worth $25.5 million (£15.7 million).

EFK Diagnostics (EFK), an AIM-listed manufacturer of healthcare equipment, has agreed to acquired the entire issued share capital of Stanbio Laboratory in a deal worth $25.5 million (£15.7 million).

US-based Stanbio provides medical device distribution and manufacturing. Its three main product sale areas are chemical reagents, haemoglobin and test strips such as pregnancy tests.

The Texas-headquartered company reported sales of $16.4 million which led to profit before tax of $2.4 million.

Julian Baines, CEO of EFK, comments: ‘The acquisition of Stanbio is transformational for EFK. As previously promised we now have access to the US Point of Care market and in addition I am sure that our relationship with Alere will help build our reputation in this very important market.’

As well as the deal for Stanbio, EFK has also agreed to acquire Alere, a US-based diagnostics business.

Under the terms of the deal for Stanbio, $14 million is payable in cash on completion, with $5.5 million paid from the issue of 16,189,675 new ordinary shares. An additional $2 million in cash is payable if the EBITDA of Stanbio exceeds targets in each of the years ending 31 December in 2011 and 2012.

Finally, Stanbio will receive a subsequent $4 million in cash if the sales of the enlarged group exceed $50 million in any calendar year before 31 December 2015.

The acquisition for EFK is its first since its December purchase of Argutus Medical, a developer of biomarkers of organ injury, for a total £2.18 million.

Todd Cardy

Todd Cardy

Todd was Editor of GrowthBusiness.co.uk between 2010 and 2011 as well as being responsible for publishing our digital and printed magazines focusing on private equity and venture capital.

Related Topics